German Neuraxpharm reinforces presence in Poland
DO NOT USE TOO SMALL
Neuraxpharm Group, a leading European specialty pharmaceutical company focused on the treatment of central nervous system (CNS) disorders, has announced the acquisition of Glenmark’s CNS product portfolio in Poland.
Following the transaction, the Glenmark CNS commercial team in Poland will join Neuraxpharm Polska’s existing sales and marketing organization to create a strong player in the Polish CNS market, Neuraxpharm said in a press release.
Glenmark’s established portfolio of 20 proprietary CNS products in Poland comprise both prescription medicines and Consumer Healthcare products. The terms of the transaction were not disclosed.
SUPPORT THE BUDAPEST BUSINESS JOURNAL
Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.